Head of Manufacturing Sciences - Athlone
About the job
- MSc/PhD in a relevant scientific or engineering discipline, with significant and proven years of experience in sterile/aseptic drug product manufacturing.
- Ability to act as the technical bridge between development and manufacturing, aligning process needs with site capability and capacity
- Strong background in tech transfer, process engineering, Manufacturing Sciences and Technology (MSAT), or manufacturing sciences, with proven ability to troubleshoot and optimise drug product processes.
- Experience developing strategies for validation campaigns, ideally in a fast-paced or high-throughput environment.
- Experience hosting or presenting during regulatory inspections, including responding to technical questions and supporting inspection strategy.
- Experience acting as a site technical authority for drug product knowledge/processes, (e.g. material changes, risk assessments, and lifecycle management)
- Hands-on experience with drug product process troubleshooting, deviation resolution, and long-term corrective actions.
- Strong understanding of how to align site capacity, equipment capability, and process needs.
- Deep understanding of current Good Manufacturing Practice/Good Laboratory Practice (cGMP/cGXP) requirements for sterile drug product manufacturing.
- Experience influencing senior stakeholders and contributing to site-level strategy
- Provide technical direction and leadership to staff and matrixed teams for seamless process integration and monitoring.
- Collaborate with site and global leadership teams, providing strategic recommendations and ensuring alignment with global goals.
- Translate business priorities into tactical objectives for the site Manufacturing Sciences teams, ensuring adherence to production schedules.
- Manage budget, staffing, and performance management, while mentoring staff for career development.
- Ensure compliance with cGXP regulations and maintain high regulatory compliance, supporting regulatory inspections.
- Foster a culture of innovation, driving strategic priorities for technology and digital transformation at scale.
About This Role:
In the role of Head of Manufacturing Sciences at the Athlone Site, you will lead a dedicated team responsible for overseeing and advancing manufacturing process technology. As a pivotal member of the Site Leadership Team, you will direct the broad responsibilities of the Manufacturing Sciences (MS) division, ensuring the seamless technology transfer, implementation of advanced process controls, and ongoing manufacturing process monitoring. Your role will be crucial in providing essential technical support, ensuring campaign success, and maintaining an inspection-ready state for manufacturing processes. By representing the Athlone site on the Global Manufacturing Sciences Leadership Team (GMS LT), you will develop and align goals with both Athlone site and GMS objectives, ensuring cohesive progress towards strategic imperatives.
This position requires working on site in Athlone for 5 days per week.
What You’ll Do:
Provide technical direction and leadership to staff and matrixed teams for seamless process integration and monitoring.
Collaborate with site and global leadership teams, providing strategic recommendations and ensuring alignment with global goals.
Translate business priorities into tactical objectives for the site MS teams, ensuring adherence to production schedules.
Manage budget, staffing, and performance management, while mentoring staff for career development.
Ensure compliance with cGXP regulations and maintain high regulatory compliance, supporting regulatory inspections.
Foster a culture of innovation, driving strategic priorities for technology and digital transformation at scale.
Who You Are:
You are a seasoned technical leader with deep expertise in sterile drug product manufacturing and a strong ability to operate at the interface of development and commercial operations. You thrive in complex, cross‑functional environments, bringing together teams across Quality, Regulatory, Engineering, and Manufacturing to solve problems and deliver robust, compliant processes. You’re a strategic thinker who can translate product and site priorities into clear technical plans, while also being hands‑on enough to troubleshoot issues, lead validation activities, and guide long‑term improvements. You’re collaborative, influential, and confident engaging with regulators and you’re motivated by the opportunity to build and shape a growing Manufacturing Sciences function.
Required Skills:
MSc/PhD in a relevant scientific or engineering discipline, with significant and proven years of experience in sterile/aseptic drug product manufacturing.
Ability to act as the technical bridge between development and manufacturing, aligning process needs with site capability and capacity
Strong background in tech transfer, process engineering, MSAT, or manufacturing sciences, with proven ability to troubleshoot and optimise drug product processes.
Experience developing strategies for validation campaigns, ideally in a fast‑paced or high‑throughput environment.
Experience hosting or presenting during regulatory inspections, including responding to technical questions and supporting inspection strategy.
Experience acting as a site technical authority for drug product knowledge/processes, (e.g. material changes, risk assessments, and lifecycle management)
Hands‑on experience with drug product process troubleshooting, deviation resolution, and long‑term corrective actions.
Strong understanding of how to align site capacity, equipment capability, and process needs.
Deep understanding of cGMP/cGXP requirements for sterile drug product manufacturing.
Experience influencing senior stakeholders and contributing to site‑level strategy
Why Biogen?
We are a global team with a commitment to excellence, and a pioneering spirit. As a mid-sized biotechnology company, we provide the stability and resources of a well-established business while fostering an environment where individual contributions make a significant impact. Our team encompasses some of the most talented and passionate achievers who have unparalleled opportunities for learning, growth, and expanding their skills. Above all, we work together to deliver life-changing medicines, with every role playing a vital part in our mission. Caring Deeply. Achieving Excellence. Changing Lives.
At Biogen, we are committed to building on our culture of inclusion and belonging that reflects the communities where we operate and the patients we serve. We know that diverse backgrounds, cultures, and perspectives make us a stronger and more innovative company, and we are focused on building teams where every employee feels empowered and inspired. Read on to learn more about Biogen.
All qualified applicants will receive consideration for employment without regard to sex, gender identity or expression, sexual orientation, marital status, race, color, national origin, ancestry, ethnicity, religion, age, veteran status, disability, genetic information or any other basis protected by federal, state or local law. Biogen is an E-Verify Employer in the United States.
About the company
Biogen is a global biotechnology company focused on neuroscience. It discovers, develops, and delivers therapies for neurological disorders, such as multiple sclerosis and other neurodegenerative diseases. Its product process starts with research and development to identify potential drugs, followed by clinical testing and regulatory approval, ultimately leading to commercialization and patient treatment. Biogen differentiates itself through a long history (founded in 1978), a deep specialization in neuroscience, and an integrated pipeline that moves ideas from discovery to approved medicines, aiming to create value for shareholders while helping communities. The company’s goal is to advance therapies for neurological diseases to improve patients’ lives and generate sustainable value for stakeholders.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
1978
Get referred to Biogen
See people who can refer or advise you
Simplify's Take
What believers are saying
- LEQEMBI Pen won Japan approval on September 16, 2026, expanding at-home dosing.
- China approved LEQEMBI subcutaneous initiation on September 3, 2026, accelerating access.
- Apellis closed on May 14, 2026, adding SYFOVRE and EMPAVELI revenue.
What critics are saying
- Biogen halted BIIB122 after May 21, 2026 Phase 2b failure in Parkinson’s disease.
- Genentech won $124.3 million against Biogen in November 2025; appeal remains pending.
- TECFIDERA exclusivity expired, generics spread, and 1,400 layoffs expose franchise erosion.
What makes Biogen unique
- Biogen pairs neuroscience depth with marketed Alzheimer’s, MS, and rare-disease franchises.
- Eisai-Biogen launched LEQEMBI IQLIK in the U.S. on August 24, 2026.
- Biogen and Stoke advanced zorevunersen into Phase 3 EMPEROR for Dravet syndrome.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Remote Work Options
- Professional Development Budget
Growth & Insights and Company News
6 month growth
-10%1 year growth
-10%2 year growth
-10%Arrowhead's blood-brain barrier tech is 'arguably better' than others, analysts say after data drop. October 15, 2026 | Arrowhead Pharmaceuticals' siRNA candidate achieved "compelling" tau reductions in an early study of healthy volunteers, with a magnitude of effect that seems to outperform other blood-brain barrier platforms, according to Stifel. Arrowhead Pharmaceuticals' investigational gene silencer lowered tau protein levels in an early study, suggesting that the biotech's approach to bypass the blood-brain barrier may be better than competing technologies. The findings "provide important clinical validation" for Arrowhead's platform for targeting the central nervous system through subcutaneously administered drugs, Stifel analysts said in a Wednesday note. Results from the Phase 1/2a study, disclosed Wednesday, showed a 40% average reduction in CSF tau at day 105 in healthy volunteers who were treated with the low 2.1-mg/kg dose of the siRNA candidate, called ARO-MAPT, on days 1, 8 and 15. In those given a 6.4-mg/kg dose on the same days, CSF tau dropped by 69% on average at day 105. Meanwhile, a 12.8-mg/kg dose of ARO-MAPT injected on days 1 and 15 triggered a mean CSF tau reduction of 73% at day 105. The maximum CSF tau reduction reached 85% in the high-dose cohort. The early trial is actively enrolling patients, with a target of 112 participants, including healthy volunteers for the study's first part and patients with early Alzheimer's disease for the second portion. Wednesday's data came from healthy volunteers. As for safety, the primary objective of the Phase 1/2a trial, Arrowhead said that ARO-MAPT was "generally well tolerated." Treatment-emergent adverse events were largely mild, with no serious side effects, deaths or dropouts due to toxicities. The data, while early, could set Arrowhead up to compete against Biogen, analysts say. Both companies are advancing tau-targeting therapies that work by suppressing the expression of the MAPT gene, which codes for the tau protein. "While details are still relatively light, the data looking compelling," Stifel told investors in a note on Wednesday, adding that the interim findings are "arguably better than what we've seen with other BBB platforms." The firm also hinted at a potential competitive edge for Arrowhead's subcutaneous siRNA asset, writing that the CSF tau knockdown "looks better than [Biogen's] BIIB080," an anti-tau antisense oligonucleotide also known as diranersen that is injected directly into the spine. ARO-MAPT, meanwhile, can be delivered via an injection under the skin. Phase 1b data for diranersen published in 2023 showed that, across various dose levels, CSF tau declined by an average of 30% to 49% at eight weeks after the final dose of Biogen's asset. Diranersen's tau-lowering effect persisted through 24 weeks after the last dose, hitting an average tau reduction of up to 56%. The trial enrolled 46 patients with mild Alzheimer's disease, and its primary endpoint was safety; CSF tau was set as a key exploratory outcome. There have been no direct head-to-head studies between ARO-MAPT and diranersen, which prompted Jefferies to be a bit more reserved about comparing the two assets. The firm in a Wednesday note pointed to differences in study populations and dose strengths. In May, Biogen announced that diranersen failed to meet its primary goal of showing a dose-response effect in cognitive and functional outcomes in the Phase 2 CELIA study. Nevertheless, the company detected "robust reductions in tau pathology" that were consistent with the Phase 1b study. Biogen also touted cognitive improvements and slowing of decline, especially in patients who received the lowest dose of diranersen. Based on these efficacy signals, Biogen has decided to push diranersen into registrational development, though the company has yet to specify a timeline for this. Arrowhead is also moving forward with ARO-MAPT, with additional healthy volunteer and Alzheimer's disease data expected next year. Arrowhead is also in talks with health regulators to enable studies in MAPT-associated frontotemporal dementia and progressive supranuclear palsy, according to the Wednesday announcement.
Investment research site StockStory picked two stocks to buy and one to avoid among companies trading near 52-week highs. It likes Mastercard and ConocoPhillips, and advises selling Biogen. Mastercard trades at $588.84 per share, or 27x forward earnings. Its revenue grew 16.1% a year over five years, and its return on equity is 182%. ConocoPhillips trades at $134.30, or 12.3x forward earnings. Its revenue grew 10.1% a year over ten years, and its revenue stands at $65.28 billion. Biogen trades at $224.63, or 16.5x forward earnings. Its revenue fell 3% a year over five years, and its earnings per share have declined.
Trigeminal Neuralgia Pipeline Outlook highlights 10+ Companies and 10+ emerging therapies across clinical development stages. September 29 Trigeminal Neuralgia is a chronic neuropathic pain disorder characterized by spontaneous and elicited paroxysms of electric shock-like or stabbing pain in a region of the face, most frequently affecting the distribution of the second (maxillary) or third (mandibular) division of the trigeminal nerve, with the right side of the face affected more often than the left. (Albany, US) September 28, 2026 - DelveInsight's "Trigeminal Neuralgia - Pipeline Insight, 2026" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Trigeminal Neuralgia pipeline landscape, covering clinical and nonclinical stage products, therapeutics assessment by product type, stage, route of administration, and molecule type, as well as inactive pipeline products. Three types of trigeminal neuralgia have been delineated: classical, secondary, and idiopathic, with bilateral trigeminal neuralgia rare and warranting concern about an underlying neurologic or non-neurologic disorder affecting the cranium. Incidence is higher among women than men and increases with age. Key Takeaways from the Trigeminal Neuralgia Pipeline Report * The Trigeminal Neuralgia pipeline includes 10+ key companies developing therapies, with 10+ products spanning Phase III, Phase II, Phase I, preclinical, and discovery stages, along with discontinued and inactive candidates. * Biogen has the most advanced Trigeminal Neuralgia drug candidate in the pipeline, with Vixotrigine (BIIB074) currently in Phase III development. * Vixotrigine is a centrally and peripherally acting small molecule that functions as a voltage- and use-dependent sodium channel blocker, being developed by Biogen for the treatment of Trigeminal Neuralgia. * Rimegepant, developed by Biohaven Pharmaceuticals, is a calcitonin gene-related peptide (CGRP) receptor antagonist in Phase II development for Trigeminal Neuralgia, with a trial initiated in June 2019. * The pipeline includes therapies across multiple stages of development, highlighting continued innovation in neuropathic pain treatment. * Emerging therapies are being developed through diverse mechanisms, including sodium channel blockers and CGRP receptor antagonists. Gain Strategic Insights into the Trigeminal Neuralgia Pipeline Landscape * Explore the complete Trigeminal Neuralgia Pipeline Outlook. * Analyze Phase III, Phase II, Phase I, preclinical, and discovery-stage assets. * Evaluate emerging companies and late-stage pipeline therapies. * Understand therapeutic assessment by product type, route of administration, and molecule type. * Track collaborations, licensing, acquisitions, and other pipeline development activities. Explore detailed pipeline insights and emerging therapies @ Trigeminal Neuralgia Pipeline Insight Report Trigeminal Neuralgia Disease Overview Pain can be triggered by routine acts, including brushing teeth, shaving, touching the face, eating or drinking, speaking, or a breeze on the face. Diagnosis is clinical, based on pain restricted to the territory of one or more divisions of the trigeminal nerve and sudden, intense, very short paroxysms. The anticonvulsant agents carbamazepine and oxcarbazepine have been considered first-choice treatments for control of paroxysmal pain, with gabapentin, pregabalin, and antidepressant agents tried as additional agents. Microvascular decompression is favored as the surgical procedure for cases not responding to medication. Trigeminal Neuralgia Emerging Drugs Analysis The Trigeminal Neuralgia pipeline features multiple emerging therapies targeting neuropathic pain through novel mechanisms and differentiated therapeutic approaches. Phase III Therapy * Vixotrigine (BIIB074): Biogen - A centrally and peripherally acting small molecule voltage- and use-dependent sodium channel blocker. It is currently the most advanced candidate in the Trigeminal Neuralgia pipeline and is being evaluated in Phase III clinical development. Phase II Therapy * Rimegepant: Biohaven Pharmaceuticals - A calcitonin gene-related peptide (CGRP) receptor antagonist currently being evaluated in Phase II development for Trigeminal Neuralgia, with clinical development initiated in June 2019. Further product details on additional pipeline candidates are provided in the full report. Trigeminal Neuralgia Therapeutic Assessment The report provides comprehensive therapeutic assessment of Trigeminal Neuralgia drugs across multiple development and product parameters. Clinical Trial Phases * Late-stage products (Phase III). * Mid-stage products (Phase II). * Early-stage products (Phase I). * Preclinical candidates. * Discovery-stage candidates. * Discontinued and inactive pipeline candidates. Route of Administration * Intravenous. * Subcutaneous. * Oral. * Intramuscular. Molecule Type * Monoclonal antibody. * Small molecule. * Peptide. Product Type * Mono. * Combination. * Mono/Combination. Trigeminal Neuralgia Pipeline Development Landscape The Trigeminal Neuralgia pipeline reflects ongoing innovation across clinical and preclinical development, with multiple companies advancing therapies targeting neuropathic pain through differentiated mechanisms of action. The pipeline spans early discovery through Phase III clinical development and includes both active and inactive candidates, providing insights into the evolving research landscape. Discover Which Companies and Pipeline Therapies Are Advancing Trigeminal Neuralgia Treatment @ Trigeminal Neuralgia Pipeline Insights Scope of the Trigeminal Neuralgia Pipeline Report * Geography Covered: Global. * Coverage: 10+ companies and 10+ pipeline drugs across clinical and nonclinical development stages. * Clinical Stages Covered: Phase III, Phase II, Phase I, preclinical, discovery, inactive, and discontinued products. * Therapeutic Assessment: Product type, clinical stage, route of administration, and molecule type. * Additional Coverage: Collaborations, acquisitions and mergers, licensing, designations, and other product-related development activities. About DelveInsight DelveInsight is a leading healthcare-focused market research and consulting firm that provides actionable market intelligence and strategic insights across the pharmaceutical, biotechnology, and healthcare industries. With expertise in epidemiology forecasting, competitive intelligence, and pipeline analysis, DelveInsight helps organizations make informed business decisions and stay ahead in an evolving healthcare landscape. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Mehul Malhotra Email: Send Email Phone: 09650213330 Address:A-1 NV 89107 City: delhi State: Indiana Country: United States Website: https://www.delveinsight.com/
Trigeminal Neuralgia Pipeline Outlook highlights 10+ Companies and 10+ emerging therapies across clinical development stages. September 29 Trigeminal Neuralgia is a chronic neuropathic pain disorder characterized by spontaneous and elicited paroxysms of electric shock-like or stabbing pain in a region of the face, most frequently affecting the distribution of the second (maxillary) or third (mandibular) division of the trigeminal nerve, with the right side of the face affected more often than the left. (Albany, US) September 28, 2026 - DelveInsight's "Trigeminal Neuralgia - Pipeline Insight, 2026" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Trigeminal Neuralgia pipeline landscape, covering clinical and nonclinical stage products, therapeutics assessment by product type, stage, route of administration, and molecule type, as well as inactive pipeline products. Geographic Reference Three types of trigeminal neuralgia have been delineated: classical, secondary, and idiopathic, with bilateral trigeminal neuralgia rare and warranting concern about an underlying neurologic or non-neurologic disorder affecting the cranium. Incidence is higher among women than men and increases with age. Key Takeaways from the Trigeminal Neuralgia Pipeline Report * The Trigeminal Neuralgia pipeline includes 10+ key companies developing therapies, with 10+ products spanning Phase III, Phase II, Phase I, preclinical, and discovery stages, along with discontinued and inactive candidates. * Biogen has the most advanced Trigeminal Neuralgia drug candidate in the pipeline, with Vixotrigine (BIIB074) currently in Phase III development. * Vixotrigine is a centrally and peripherally acting small molecule that functions as a voltage- and use-dependent sodium channel blocker, being developed by Biogen for the treatment of Trigeminal Neuralgia. * Rimegepant, developed by Biohaven Pharmaceuticals, is a calcitonin gene-related peptide (CGRP) receptor antagonist in Phase II development for Trigeminal Neuralgia, with a trial initiated in June 2019. * The pipeline includes therapies across multiple stages of development, highlighting continued innovation in neuropathic pain treatment. * Emerging therapies are being developed through diverse mechanisms, including sodium channel blockers and CGRP receptor antagonists. Gain Strategic Insights into the Trigeminal Neuralgia Pipeline Landscape * Explore the complete Trigeminal Neuralgia Pipeline Outlook. * Analyze Phase III, Phase II, Phase I, preclinical, and discovery-stage assets. * Evaluate emerging companies and late-stage pipeline therapies. * Understand therapeutic assessment by product type, route of administration, and molecule type. * Track collaborations, licensing, acquisitions, and other pipeline development activities. Explore detailed pipeline insights and emerging therapies @ Trigeminal Neuralgia Pipeline Insight Report Trigeminal Neuralgia Disease Overview Pain can be triggered by routine acts, including brushing teeth, shaving, touching the face, eating or drinking, speaking, or a breeze on the face. Diagnosis is clinical, based on pain restricted to the territory of one or more divisions of the trigeminal nerve and sudden, intense, very short paroxysms. The anticonvulsant agents carbamazepine and oxcarbazepine have been considered first-choice treatments for control of paroxysmal pain, with gabapentin, pregabalin, and antidepressant agents tried as additional agents. Microvascular decompression is favored as the surgical procedure for cases not responding to medication. Trigeminal Neuralgia Emerging Drugs Analysis The Trigeminal Neuralgia pipeline features multiple emerging therapies targeting neuropathic pain through novel mechanisms and differentiated therapeutic approaches. Phase III Therapy Counseling Services * Vixotrigine (BIIB074): Biogen - A centrally and peripherally acting small molecule voltage- and use-dependent sodium channel blocker. It is currently the most advanced candidate in the Trigeminal Neuralgia pipeline and is being evaluated in Phase III clinical development. Phase II Therapy * Rimegepant: Biohaven Pharmaceuticals - A calcitonin gene-related peptide (CGRP) receptor antagonist currently being evaluated in Phase II development for Trigeminal Neuralgia, with clinical development initiated in June 2019. Further product details on additional pipeline candidates are provided in the full report. Trigeminal Neuralgia Therapeutic Assessment The report provides comprehensive therapeutic assessment of Trigeminal Neuralgia drugs across multiple development and product parameters. Clinical Trial Phases * Late-stage products (Phase III). * Mid-stage products (Phase II). * Early-stage products (Phase I). * Preclinical candidates. * Discovery-stage candidates. * Discontinued and inactive pipeline candidates. Route of Administration * Intravenous. * Subcutaneous. * Oral. * Intramuscular. Molecule Type * Monoclonal antibody. * Small molecule. * Peptide. Product Type * Mono. * Combination. * Mono/Combination. Trigeminal Neuralgia Pipeline Development Landscape The Trigeminal Neuralgia pipeline reflects ongoing innovation across clinical and preclinical development, with multiple companies advancing therapies targeting neuropathic pain through differentiated mechanisms of action. The pipeline spans early discovery through Phase III clinical development and includes both active and inactive candidates, providing insights into the evolving research landscape. Discover Which Companies and Pipeline Therapies Are Advancing Trigeminal Neuralgia Treatment @ Trigeminal Neuralgia Pipeline Insights Counseling Services Scope of the Trigeminal Neuralgia Pipeline Report * Geography Covered: Global. * Coverage: 10+ companies and 10+ pipeline drugs across clinical and nonclinical development stages. * Clinical Stages Covered: Phase III, Phase II, Phase I, preclinical, discovery, inactive, and discontinued products. * Therapeutic Assessment: Product type, clinical stage, route of administration, and molecule type. * Additional Coverage: Collaborations, acquisitions and mergers, licensing, designations, and other product-related development activities. About DelveInsight DelveInsight is a leading healthcare-focused market research and consulting firm that provides actionable market intelligence and strategic insights across the pharmaceutical, biotechnology, and healthcare industries. With expertise in epidemiology forecasting, competitive intelligence, and pipeline analysis, DelveInsight helps organizations make informed business decisions and stay ahead in an evolving healthcare landscape. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Mehul Malhotra Email: Send Email Phone: 09650213330 Address:A-1 NV 89107 City: delhi State: Indiana Country: United States Website: https://www.delveinsight.com/
Basecamp Research raises $140M to advance AI-designed therapeutics. Sep 23, 2026, 09:00 ET * Oversubscribed Series C led by S32 with backing from NVIDIA and others * Funding will advance a pipeline of EDEN-designed therapeutics, starting with in vivo cell therapy, and expand pharmaceutical partnerships * The company has demonstrated strong preclinical results across multiple modalities and disease areas LONDON and BOSTON, Sept. 23, 2026 /PRNewswire/ - Basecamp Research, a frontier AI company developing AI-designed medicines, today announced a $140M Series C financing to train a new generation of EDEN models and advance a pipeline of AI-designed therapeutics towards clinical development. Basecamp's ambition is to develop cures for diseases that remain incurable by designing medicines that reprogram the body to repair itself. The company combines frontier AI models trained on proprietary biological data with technology for writing DNA sequences into cells. "We believe the future of medicine lies in reprogramming the body to repair itself. We design the models and the medicines to teach it how," said Glen Gowers, co-founder and CEO of Basecamp Research. "AI-based approaches promise to change what's possible for patients who currently have few alternatives. This funding brings this technology closer to those who need it most." The oversubscribed round was led by S32, with participation from Anthropic's Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, NVIDIA, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI and True Ventures. Additional investment comes from senior leaders from across pharma, biotech, and global industry, including André Hoffmann, Vice-Chairman of Roche, who said: "The biotechnology revolution that began fifty years ago transformed how we make medicines. Personalised, AI-designed therapeutics represent the next transformation of that journey. Basecamp Research has built the full platform to deliver it, from biological data to trained models to designed therapies. This will be key in helping the industry to continue to innovate." Applying EDEN to develop new therapies Basecamp Research is applying EDEN, its biological foundation model, to in vivo cell therapy - reprogramming a patient's cells inside the body. Today's cell therapies are limited both in the complexity of what they can deliver and by a manufacturing process that costs hundreds of thousands of dollars per patient. By pairing EDEN's ability to design long and complex DNA sequences with large serine recombinases that can precisely integrate them into the genome, Basecamp's platform aims to underpin the future of cell therapies, making them more sophisticated, more customisable and simpler to administer. This has the potential to transform how we treat cancer, autoimmune disease, and more. The company has demonstrated strong preclinical results across multiple modalities and disease areas. To expand its pharmaceutical partnerships, Basecamp has appointed Richard Pearce, formerly of Biogen, as Chief Business Officer. Andy Conrad, General Partner at S32 and former CEO of Google's Verily, who joins the Board of Directors, said: "AI is opening up new possibilities across every part of society, but perhaps nowhere is the potential more meaningful than in human health. The ability to combine AI, biological data and scientific insight could transform how we understand disease, discover medicines and ultimately improve and extend people's lives. Basecamp Research is building an important technology platform at the center of that opportunity." The AI and data powering Basecamp Research's therapies At the centre of Basecamp Research's AI platform is the Trillion Gene Atlas, the world's largest proprietary biological AI training dataset. Built with partners including NVIDIA, Anthropic, PacBio and Ultima Genomics, the Atlas draws on biological data collected through access and benefit-sharing partnerships in more than 30 countries across all seven continents. Trained on this data, the company's EDEN models recognise patterns across a huge breadth of previously unseen biology. Unlike AI systems developed for a single scientific task, EDEN models aim to deliver a universal understanding of how DNA works across all of life. This means that the models can generate potential therapeutic candidates directly from information about a disease, an approach already demonstrated through Basecamp's collaboration with Anthropic on Claude Science. The EDEN models' capabilities include designing cell and gene therapies, enzymes and peptides. About Basecamp Research Basecamp Research trains frontier AI models for therapeutic design. The EDEN models are trained on the Trillion Gene Atlas, the world's largest proprietary genomic dataset, collected through partnerships in more than 30 countries worldwide. Its pipeline of EDEN-designed therapeutics, beginning with in vivo cell therapy, is advancing towards clinical development. Basecamp Research is headquartered in London with offices and labs in Cambridge, MA. SOURCE Basecamp Research